FDA Clears MRI Use with Cardiac Contractility Modulation Device
The expanded 510(k) clearance from the FDA for the Optimizer Smart Mini system allows full-body MRI use for patients with heart failure who are receiving cardiac contractility modulation (CCM).
The Food and Drug Administration (FDA) has approved a 510(k) conditional clearance for whole-body magnetic resonance imaging (MRI) use in heart failure patients receiving proprietary cardiac contractility modulation (CCM) therapy with the Optimizer Smart Mini device (Impulse Dynamics).
The expanded labeling includes the use of 1.5 and 3.0 Tesla (T) full-body MRI with the Optimizer Smart Mini system, an implantable device that employs electrical pulses to facilitate heart contraction in patients with New York Heart Association (NYHA) Class III heart failure, according to Impulse Dynamics.
The company noted the Optimizer Smart Mini system was previously cleared by the FDA to improve six-minute hall walk and quality of life for those with a left ventricular ejection fraction between 25 to 45 percent and continue to experience symptoms despite receiving guideline-directed medical treatment.
Impulse Dynamics said the expanded indication for conditional MRI use is a significant benefit in this patient population.
“We are pleased to receive approval for this important labeling change reflecting a necessary option for heart failure patients who likely receive multiple surgeries and benefit from the use of MRI imaging in the course of their treatment,” noted Jason Spees, the CEO of Impulse Dynamics. “This furthers our commitment to supporting the heart failure patients who benefit from important and life changing CCM therapy with the Optimizer Smart Mini system.”
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
